UCB Biopharma SRL

This study tests a new medicine called bimekizumab against an existing one (ustekinumab) for children and teens aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if bimekizumab works better at clearing skin symptoms. About 168 participants will receive inj…

This study is checking the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). It involves 760 participants who have already completed earlier studies of the drug. Researchers will monitor side effects over time to see if th…

This study tests a drug called rozanolixizumab in 12 children aged 2 to 18 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive injections, and resea…

This study tests a drug called bimekizumab in teenagers (ages 9 to 17) with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils. The goal is to see how the drug moves through the body and if it is safe. About 40 participants will receive the dr…

This study looks at the long-term safety of the drug brivaracetam in children and teenagers with childhood absence epilepsy or juvenile absence epilepsy. About 120 participants who have already taken the drug in earlier studies will continue treatment and be monitored for side ef…

This study tests an investigational drug called rozanolixizumab in adults with MOG antibody-associated disease (MOGAD), a rare condition where the immune system attacks the brain and spinal cord. The main goal is to see if the drug can prevent or delay relapses (flare-ups) compar…

This study looks at the long-term safety of a drug called rozanolixizumab in children aged 2 and older with generalized myasthenia gravis, a condition that causes muscle weakness. The drug is given in 6-week treatment cycles. The main goal is to track serious side effects and see…

This study tests the long-term safety of an experimental drug called UCB0107 (bepranemab) in people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and balance. Participants who completed a prior study receive regular infusions of the drug. …

This study looks at the long-term safety of a daily injection called zilucoplan in children with a rare muscle-weakening disease called generalized myasthenia gravis. It includes up to 8 children who have already completed a previous study. The goal is to see if the drug remains …

This study tests the drug bimekizumab in 89 adults with moderate to severe plaque psoriasis, some of whom also have psoriatic arthritis. Researchers will measure changes in gene activity in skin samples after 48 weeks of treatment. The goal is to understand how the drug affects t…

This program provides brivaracetam (Briviact) to epilepsy patients who were already taking it in earlier studies, bridging the gap until the drug is commercially available. Patients continue their individual doses, up to 200 mg per day, with adjustments based on seizure control a…

This program provides ongoing access to certolizumab pegol (Cimzia) for adults with rheumatoid arthritis who took part in earlier open-label studies. Participants receive the standard maintenance dose of 200 mg every two weeks. The goal is to allow continued disease management or…

This study tests the long-term safety of an inhaled medication called Staccato alprazolam for people aged 12 and older who have prolonged seizures. About 300 participants will use the inhaler when a seizure starts to see if it stops the seizure quickly and without serious side ef…

This early-phase study is testing a new drug called UCB5285 in healthy volunteers, including people of Japanese descent. The main goal is to see if single doses are safe and how the body processes the drug. No therapeutic benefit is expected; this is purely a safety and tolerabil…